GNTP is a biopharmaceutical company established in April 1998 with the aim of developing innovative medicines and technologies for the treatment of neurological disorders such as stroke and Alzheimer’s disease.
While new drug development for brain diseases has traditionally targeted an individual identified disease mechanism, GNT has focused its efforts on "multi-targeting" multiple concurrent disease mechanisms, an approach proven effective and sometimes even necessary in other fields such as cancer.
Drag from side to side.
We will aim high with a bold pioneering spirit.
We will pursue our goals with confidence and positivity.
We will innovate to address the healthcare needs of mankind.
We will develop talent with mutual encouragement and support.
We will strive to act truthfully and with appropriate intent.
We will do our best to be diligent in all endeavors.